CanDo
A CANcer Development mOnitor
| Coordinatore | UNIVERSITAT DE VALENCIA
Organization address
address: AVENIDA BLASCO IBANEZ 13 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 5˙299˙286 € |
| EC contributo | 4˙000˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2013-10 |
| Funding Scheme | CP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2017-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAT DE VALENCIA
Organization address
address: AVENIDA BLASCO IBANEZ 13 contact info |
ES (VALENCIA) | coordinator | 0.00 |
| 2 |
Bayer Pharma AG
Organization address
address: Muellerstrasse 178 contact info |
DE (Berlin) | participant | 0.00 |
| 3 |
GILUPI GMBH
Organization address
address: AM MUEHLENBERG 11 contact info |
DE (POSTDAM) | participant | 0.00 |
| 4 |
IKERLAN SCL
Organization address
address: Paseo J.M. Arizmendiarrieta 2 contact info |
ES (MONDRAGON) | participant | 0.00 |
| 5 |
INTERUNIVERSITAIR MICRO-ELECTRONICACENTRUM IMEC VZW
Organization address
address: KAPELDREEF 75 contact info |
BE (LEUVEN) | participant | 0.00 |
| 6 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: BRINELLVAGEN 8 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 7 |
LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.
Organization address
address: Albert Einstein strasse 9 contact info |
DE (JENA) | participant | 0.00 |
| 8 |
MICROFLUIDIC CHIPSHOP GMBH
Organization address
address: STOCKHOLMER STRASSE 20 contact info |
DE (JENA) | participant | 0.00 |
| 9 |
STOCKHOLMS LAENS LANDSTING
Organization address
address: Hantverkargatan 45 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 10 |
STOCKHOLMS UNIVERSITET
Organization address
address: Universitetsvaegen 10 contact info |
SE (STOCKHOLM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop an instrument that will permit the identification and concentration determination of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy determination and cancer diagnosis/monitoring.A cellular link between the primary malignant tumor and the peripheral metastases, responsible for 90% of cancer-related deaths, has been established in the form of circulating tumor cells (CTCs) in peripheral blood. Furthermore the relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumor progression thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumor progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. Similarly problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often preventing access to market. There is therefore a clear need for a novel analytical platform capable of highly reproducible and reliable identification of CTC concentrations of interest in an easily accessible format.With all relevant industrial stakeholders and users onboard CanDo is uniquely capable of delivering such a platform. Its novel cell separation/SERS analysis technologies plus nucleic acid based molecular characterization will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and cancer diagnostics but due to modular technologies in others e.g. transport, security and safety and environment.